Literature DB >> 33643950

Phylogenetic Analysis and Antimicrobial Resistance Profiles of Escherichia coli Strains Isolated from UTI-Suspected Patients.

Reza Ranjbar1, Sedigheh Nazari2, Omid Farahani3.   

Abstract

BACKGROUND: Escherichia coli as one of the most predominant pathogens is the major cause of urinary tract infections (UTI) worldwide. E. coli strains could be classified into distinct phylo-groups based on PCR method. Additionally, studying the antimicrobial resistance profiles of these strains is essential for finding the effective selection of treatment and evaluating the differences among resistance patterns of particular phylogenetic groups. This study aimed to determine the phylogroups of E. coli isolated from patients with UTI in Tehran, Iran.
METHODS: The urine samples were collected from patients suspected to UTI from four hospitals in Tehran, Iran; Mofid, Vali-Asr, Bu-Ali and Tehran Heart Center (THC) Hospitals during 2014-2016. Assessing the antimicrobial resistance profile of the identified strains was accomplished using ampicillin, ceftriaxone, cefotaxime, and ceftazidime among β-lactam group; gentamicin, and streptomycin among aminoglycosides; nalidixic acid and norfloxacin from quinolones; and chloramphenicol disks. The phylogenetic characterization of 60 E. coli isolates obtained from patients with UTI was done by triplex PCR method.
RESULTS: E. coli strains showed high resistance toward streptomycin (93.33%), ampicillin (86.6%) and nalidixic acid (73.33%) while resistance against chloramphenicol showed the lowest (10%). The prevalent groups were B2 (n=50/60, 83%), followed by D (n=6/60, 10%), B1 (n=3/60, 5%), and A (n=1, 1.6%).
CONCLUSION: The most predominant phylogenetic group was B2 with the major frequent detected with the major drug resistant (48%) compared to other Phylogenetic groups.
Copyright © 2020 Ranjbar et al. Published by Tehran University of Medical Sciences.

Entities:  

Keywords:  Escherichia coli; Phylo-group; Triplex polymerase chain reaction; Urinary tract infections (UTI)

Year:  2020        PMID: 33643950      PMCID: PMC7898090          DOI: 10.18502/ijph.v49i9.4094

Source DB:  PubMed          Journal:  Iran J Public Health        ISSN: 2251-6085            Impact factor:   1.429


Introduction

Extraintestinal pathogenic Escherichia coli (Ex-PEC) strains are causing a great range of infections such as bacteriuria, bloodstream and urinary tract infections (1–3). Accordingly, it has been reported as the prevalent cause of bacteremia worldwide with the persistent growing rate accounting for 30% of all bacteremia (4, 5). Urinary tract infections (UTIs) has been indicated as the most frequent bacterial infectious diseases (6) under the effect of sex and age, mostly found in females of all ages (7). The involuted treatment of UTI due to the increasing prevalence of antibacterial resistance of E. coli strains of particular phylogenetic groups (8–11) has been considered as a matter of importance (12). Antimicrobial susceptibility factor is very important to consider the proper drug selection for treating the patients (5, 13–18). In recent years, various methods have been developed for determining the molecular epidemiology of microbial pathogens (19). Considering the advantages and disadvantages of the molecular typing processes, the requirements and resources of the laboratories and the aims of the investigation are the determinants for choosing the proper method. New data obtained from DNA profiling of E. coli reported from different hosts and habitats has advanced our analysis of ExPEC lineages (11, 20–22). Determining the phylogroups of an E. coli strain, Clermont et al. (23) reported a novel and easy multiplex polymerase chain reaction (PCR) method based on the presence and/or absence of chuA and yjaA genes and a DNA fragment, TspE4.C2. Recent development of genome study has determined the phylogroups of E. coli, represented as A, B1, B2, C, D, E and F (24–28). E and F are recognized as new groups; F designated as sister group of B2; and C designated as closely related group but distinct from B1 (29). This study aimed to determine the phylogroups of E. coli isolated from patients with UTI according to the method of Clermont et al. (23); then to assess the antimicrobial resistance profile of the identified strains.

Materials and Methods

Origin of isolates and bacterial strains

To doing the study, we used the stored E. coli strains that have been collected previously from patients suspected to UTI from four hospitals in Tehran, Iran; Mofid, Vali-Asr, Bu-Ali and Tehran Heart Center (THC) hospitals during 2014–2016. Sterile samples were transported to the Microbiology Laboratory. Sixty E. coli isolates were collected and subjected to this research. All isolates were cultured on standard media, including LB agar, Muller-Hinton’s agar, and LB Broth (Merck, Germany), and were incubated at 37 °C for 24 hours. Biochemical characteristics of E. coli strains were used for isolation and identification test. For long-term storage, isolated strains persevered at −20 °C in 20% skim milk (Merck, Germany) including 15%–20% glycerol.

Antimicrobial Susceptibility evaluation

Kirby-Bauer disk diffusion method was used for evaluation of susceptibility in culture media of Muller-Hinton’s agar. Susceptibility testing was performed for 9 antimicrobial drugs including ampicillin, gentamicin, streptomycin, norfloxacin, ceftazidime, chloramphenicol, ceftriaxone, nalidixic acid, and cefotaxime. E. coli ATCC 25922 and ATCC 35218 were used as the quality control strains.

DNA isolation and phylogroup determination of E. coli isolates

Boiling method was used for DNA extraction of pure colonies. In summary, overnight pure cultures were heated at 95 °C for 16–24 h, centrifuged at 13,000 rpm for 2 min and kept at −20 °C. The obtained supernatant was utilized as template DNA for subsequent PCR. The integrity of extracted DNA was evaluated by electrophoresis on 2% agarose gel. Determining the distribution of isolated E. coli phylogroups was performed using a reaction mixture contained 10 μL of 2x buffer (supplied with Taq DNA polymerase and MgCl2), 1 μL of DNA genome (approximately 100 ng), 10 pmol of each appropriate primer with the total volume of 20 μL (17). Table 1 shows the primer sequences used in this study for assignment of new phylogroups.
Table 1:

Primer sequences used in triplex phylotyping method

PCR reactionPrimer IDTargetPrimer sequencePCR product (bp)
TriplexchuA.1bchuA5-ATGGTACCGGACGAACCAAC-3288
chuA.25-TGCCGCCAGTACCAAAGACA-3
yjaA.1byjaA5-CAAACGTGAAGTGTCAGGAG-3211
yjaA.2b5-AATGCGTTCCTCAACCTGTG-3
TspE4C2.1bTspE4C5-CACTATTCGTAAGGTCATCC-3152
TspE4C2.2b25-AGTTTATCGCTGCGGGTCGC-3
Primer sequences used in triplex phylotyping method The Mastercycler gradient (Eppendorf, USA) under the following conditions were used for PCR amplifications: initial denaturation at 95 °C for 5 min and 30 cycles for each denaturation at 94 °C for 30 sec, annealing at 56 °C for 30 sec, amplification at 72 °C for 40 sec, and final extension at 72 °C for 5 minutes. Subsequently, PCR products were analyzed by electrophoresis equipped with a 2% agarose gel and visualized using GelDoc 2000 transilluminator (Bio-Rad Laboratories, Milan, Italy). A molecular weight standard (100 bp ladder, Fermentas, Lithuania) was included on each gel. Interpreting results for phylogrouping Phylogenetic groups were designated by the presence and/ or absence of chuA and yjaA genes and TspE4.C2 in triplex PCR (23).

Results

Drug Sensitivity Results

As illustrated in Fig. 1, the isolated samples were highly resistant to streptomycin 93.33%, ampicillin 86.6% and nalidixic acid 73.33% while chloramphenicol showed the lowest resistance (10%). Based on antibiotic categories (Table 2), the antibiotic resistances were related to β-lactams (66.9%), followed by quinolones (57.4%), aminoglycosides (54.1%) and chloramphenicol (10%), respectively.
Fig. 1:

Prevalence of resistance profiles

Table 2:

Prevalence of resistance among various phylogenetic groups of E. coli isolates

Antibiotics categoriesAntibioticB2DB1ATotal
AminoglycosidesGentamicin8(13.3%)-1(1.6%)-9(15%)
Streptomycin46(78%)6(10%)3(5%)1(1.6%)57(93.3%)
β-lactam groupAmpicillin44(73.3%)5(8.3%)2(3.3%)1(1.6%)52(86.6%)
Ceftriaxone34(56.6%)4(6.6%)1(1.6%)-39(65%)
Cefotaxime32(53.3%)4(6.6%)1(1.6%)-37(61.6%)
Ceftazidime29(48.3%)3(5%)1(1.6%)-33(55%)
QuinolonesNorfloxacin24(40%)1(1.6%)--25(41.6%)
Nalidixic acid38(63.3%)4(6.6%)1(1.6%)1(1.6%)44(73.3%)
ChloramphenicolChloramphenicol4(6.6%)2(3.3)--6(10%)
Prevalence of resistance profiles Prevalence of resistance among various phylogenetic groups of E. coli isolates

Phylogenetic Classification

Based on the obtained results from PCR, the studied strains were divided into four phylogenetic groups with the prevalence distribution of B2 (n=50/60, 83%), followed by D (n=6/60, 10%), B1 (n=3/60, 5%), and A (n=1, 1.6%) (Fig. 2).
Fig. 2:

Phylogenetic analysis of pathogenic E. coli isolates

Phylogenetic analysis of pathogenic E. coli isolates Phylotyping analysis revealed that the most prevalent multiple drug-resistant strain belonged to phylogroup B2 (48%). We figured out the presence of a distinct difference between phylogenetic groups and resistance to all the studied antibiotics except chloramphen- icol. Group B2 showed high resistance to all studied antibiotics except for chloramphenicol. Group A isolates showed only low resistance to three drugs, i.e. nalidixic acid, ampicillin, and streptomycin (Table 2).

Discussion

As a worldwide health issue, the emergence, propagation, accumulation, and maintenance of antimicrobial-resistant pathogenic bacteria have been mostly considered for intensive therapeutic, prophylactic, and subtherapeutic uses of antimicrobial agents. Substantially, the increased selective pressures on both pathogenic and commensal bacteria have being employed for maintenance of antimicrobial-resistant bacteria (30). Herein, the identification of E. coli through standard culture and biochemical tests from human urine samples was conducted, followed by triplex PCR to assign each isolate to a certain phylogenetic group giving in hand the recent phylogenetic studies on E. coli (31, 32). Based on our finding, applying triplex PCR method divided all E. coli strains into four phylogroups, B2, B1, D, and A (23, 27). Our results of phylogenetic analysis showed the distribution of all pathogenic isolates into B2 (n=50/60, 83%), followed by D (n=6/60, 10%), B1 (n=3/60, 5%), and A (n=1, 1.6%). The relation between antibiotic resistance and phylogroups showed that all E. coli isolates of group B1 were highly resistant to all antibiotic agents used especially penicillin and streptomycin. In contrast, only 1.6% isolates in group A were resistant to streptomycin, ampicillin and nalidixic acid. Our findings are in line with other studies reported B2 and D as the most virulent isolates of E. coli. Overall, 105 E. coli strains were evaluated with the phylogenic analysis showed four groups of B2 (51%) and D (20%) followed by A and D (33). B2 as the most prevalence phylogroup for patients infected by UTI in USA (34,35). Virulent extraintestinal E. coli strains belonged typically to group B2 and D and less often to group B1 (36,37). “A” has been reported in some researches (38, 39) as the most prevalence phylogroup which may refer to different distribution of E. coli strain within different social and geographic conditions. In this study, 93.33% and 86.6% of E. coli strains were resistant to streptomycin and ampicillin, respectively. The high frequency of ampicillin resistance among E. coli isolates has also been recently reported in various Asian and European countries, including Iran (14), China (40), Switzerland (41), and Italy (42), indicating inadequate treatment using these antibiotics.

Conclusion

Group B2 was the most predominant phylogenetic group and among the commonly used antibiotics for patients with UTI, isolated samples showed the highest resistance toward streptomycin. Regular monitoring of antibiotic resistance patterns will be useful to prescribe the most appropriate antibiotic and to avoid further development of antimicrobial drug resistance.

Ethical considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.
  35 in total

Review 1.  Extraintestinal pathogenic Escherichia coli: "the other bad E coli".

Authors:  James R Johnson; Thomas A Russo
Journal:  J Lab Clin Med       Date:  2002-03

2.  Subtyping of uropathogenic Escherichia coli according to the pathogenicity island encoding uropathogenic-specific protein: comparison with phylogenetic groups.

Authors:  Sojun Kanamaru; Hisao Kurazono; Masayuki Nakano; Akito Terai; Osamu Ogawa; Shingo Yamamoto
Journal:  Int J Urol       Date:  2006-06       Impact factor: 3.369

Review 3.  Bacterial characteristics of importance for recurrent urinary tract infections caused by Escherichia coli.

Authors:  Karen Ejrnæs
Journal:  Dan Med Bull       Date:  2011-04

4.  Animal and human pathogenic Escherichia coli strains share common genetic backgrounds.

Authors:  Olivier Clermont; Maiwenn Olier; Claire Hoede; Laure Diancourt; Sylvain Brisse; Monique Keroudean; Jérémy Glodt; Bertrand Picard; Eric Oswald; Erick Denamur
Journal:  Infect Genet Evol       Date:  2011-02-13       Impact factor: 3.342

5.  Phylogenetic origin and virulence genotype in relation to resistance to fluoroquinolones and/or extended-spectrum cephalosporins and cephamycins among Escherichia coli isolates from animals and humans.

Authors:  James R Johnson; Michael A Kuskowski; Krista Owens; Abby Gajewski; Patricia L Winokur
Journal:  J Infect Dis       Date:  2003-08-15       Impact factor: 5.226

6.  Susceptibility of Escherichia coli strains isolated from outpatient children with community-acquired urinary tract infection in southern Switzerland.

Authors:  Andrea G Borsari; Barbara Bucher; Pierluigi Brazzola; Giacomo D Simonetti; Marisa Dolina; Mario G Bianchetti
Journal:  Clin Ther       Date:  2008-11       Impact factor: 3.393

7.  Virulence factors and biofilm production among Escherichia coli strains causing bacteraemia of urinary tract origin.

Authors:  Matija Rijavec; Manca Müller-Premru; Breda Zakotnik; Darja Žgur-Bertok
Journal:  J Med Microbiol       Date:  2008-11       Impact factor: 2.472

8.  The Escherichia coli phylogenetic group B2 with integrons prevails in childhood recurrent urinary tract infections.

Authors:  Siiri Kõljalg; Kai Truusalu; Jelena Stsepetova; Kristiine Pai; Inga Vainumäe; Epp Sepp; Marika Mikelsaar
Journal:  APMIS       Date:  2013-09-11       Impact factor: 3.205

9.  Phylogenetic group, virulence factors and antimicrobial resistance of Escherichia coli associated with bovine mastitis.

Authors:  Yongxia Liu; Gang Liu; Wenjun Liu; Yong Liu; Tariq Ali; Wei Chen; Jinhua Yin; Bo Han
Journal:  Res Microbiol       Date:  2014-04-03       Impact factor: 3.992

10.  Multidrug-resistant urinary tract isolates of escherichia coli from Ribeirão Preto, São Paulo, Brazil.

Authors:  Edilene Santo; Miriam Mendonça Salvador; José Moacir Marin
Journal:  Braz J Infect Dis       Date:  2007-12       Impact factor: 1.949

View more
  3 in total

1.  Prevalence of Bacterial Urinary Tract Infection and Antimicrobial Susceptibility Patterns Among Diabetes Mellitus Patients Attending Zewditu Memorial Hospital, Addis Ababa, Ethiopia.

Authors:  Gebremdhin Yenehun Worku; Yerega Belete Alamneh; Woldaregay Erku Abegaz
Journal:  Infect Drug Resist       Date:  2021-04-15       Impact factor: 4.003

Review 2.  Phylogenetic Group Distribution of Uropathogenic Escherichia coli and Related Antimicrobial Resistance Pattern: A Meta-Analysis and Systematic Review.

Authors:  Mehrdad Halaji; Amirhossein Fayyazi; Mehdi Rajabnia; Donya Zare; Abazar Pournajaf; Reza Ranjbar
Journal:  Front Cell Infect Microbiol       Date:  2022-02-25       Impact factor: 5.293

3.  Phylogeny and antimicrobial resistance of extended-spectrum beta-lactamaseproducing Escherichia coli from hospitalized oncology patients in Perú

Authors:  Jose Matta-Chuquisapon; Esther Valencia-Bazalar; Carlos Sevilla-Andrade; Helí Jaime Barrón-Pastor
Journal:  Biomedica       Date:  2022-09-02       Impact factor: 1.173

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.